Perceptions of Leadership in Quality Culture for Infection Prevention Among Intensive Care Nurses and Unit-Based Assessment of Antimicrobial Resistance Indicators in Intensive Care Units

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeUp to 125
SponsorYeliz Sapulu Alakan

About this trial

This study aims to examine intensive care nurses' perceptions of leadership in quality culture for infection prevention and to investigate antimicrobial resistance indicators at the intensive care unit level. Healthcare-associated infections (HAIs) remain a major global patient safety problem and are associated with prolonged hospital stays, increased healthcare costs, and higher mortality. The increasing prevalence of antimicrobial resistance (AMR) further complicates infection prevention and patient care.

Intensive care units are particularly vulnerable to healthcare-associated infections and antimicrobial resistance because of the high frequency of invasive procedures, the vulnerability of critically ill patients, and the extensive use of broad-spectrum antibiotics. Nurses play a central role in infection prevention and antimicrobial stewardship because they are continuously involved in patient care. However, previous studies have reported a gap between nurses' knowledge of infection prevention and adherence to recommended practices in clinical settings. Organizational culture and leadership may contribute to this gap.

Most previous studies have focused on healthcare professionals' self-reported perceptions of infection prevention. However, limited evidence is available regarding the relationship between nurses' perceptions of leadership and quality culture and objective antimicrobial resistance indicators at the intensive care unit level. Therefore, this study will assess nurses' perceptions using the Leadership in Quality Culture for Infection Prevention (LCQ-IP) instrument and examine their relationship with retrospective microbiological data from the participating intensive care units, including antimicrobial resistance rates and resistance profiles. The findings may provide evidence on the role of organizational leadership and quality culture in infection prevention and antimicrobial resistance management in intensive care settings.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Nurses who have been actively working in an intensive care unit for at least 1 year.

Nurses who voluntarily agree to participate in the study.

Disqualifiers

Student nurses or nursing interns.

Nurses working temporarily or on a rotational basis in the intensive care unit.

Nurses who have been actively working in an intensive care unit for at least 1 year.

Trial population

The study population will consist of nurses actively working in intensive care units in participating hospitals in Bursa and Iğdır, Türkiye. Eligible participants will be nurses who have been actively working in an intensive care unit for at least 1 year and who voluntarily agree to participate in the study. Student nurses, nursing interns, nurses working temporarily or on a rotational basis in intensive care units, and nurses with less than 1 year of intensive care experience will be excluded.

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

127 Participants
are grouped into 2 trial groups
Group A: Bursa
Group B: Iğdır

Trial outcomes

Primary outcomes

1

Leadership in Quality Culture for Infection Prevention (LCQ-IP) score among intensive care nurses

Leadership for a culture of quality in infection prevention will be assessed using the Turkish version of the Leading a Culture of Quality for Infection Prevention Scale. The scale consists of 16 items rated on a 5-point Likert scale. Total scores range from 16 to 80, with higher scores indicating a more positive perception of leadership for a culture of quality in infection prevention.

Time frame
Baseline

Secondary outcomes

1

Antimicrobial Susceptibility Profiles of Bacterial Isolates from Intensive Care Units

Time frame
The 1-year period preceding study enrollment

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Yeliz Sapulu Alakan

Lead sponsor

Uludag University

Sponsor institution

This trial is not recruiting at the moment. You can still explore other options: